½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1541587

»ý¹° ¾ÈÀü ijºñ´Ö ½ÃÀå º¸°í¼­ : À¯Çü, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº°(2024-2032³â)

Biological Safety Cabinet Market Report by Type (Class I, Class II, Class III), End User (Pharmaceutical and Biopharmaceutical Companies, Diagnostic and Testing Laboratories, Academic and Research Institutions), and Region 2024-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 141 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

»ý¹° ¾ÈÀü ijºñ´Ö ¼¼°è ½ÃÀå ±Ô¸ð´Â 2023³â 2¾ï 3,930¸¸ ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2032³â±îÁö ½ÃÀå ±Ô¸ð°¡ 4¾ï 3,080¸¸ ´Þ·¯¿¡ ´ÞÇØ 2024³âºÎÅÍ 2032³â±îÁö 6.5%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù.

»ý¹° ¾ÈÀü ijºñ´Ö(BSC)Àº ´Ù¾çÇÑ º´¿ø±Õ¿¡ ÀÇÇÑ ¿À¿°À¸·ÎºÎÅÍ ÀÛ¾÷ÀÚ¿Í Àåºñ¸¦ º¸È£Çϱâ À§ÇØ ¼³°èµÈ ÅëdzÀÌ ÀߵǴ ½ÇÇè½Ç ÀÛ¾÷ °ø°£À» ¸»ÇÕ´Ï´Ù. ÀÌ Ä³ºñ´ÖÀº À¯ÇØÇÑ ¹ÙÀÌ·¯½º, ¹ÚÅ׸®¾Æ ¹× ±âŸ ¹Ì»ý¹°¿¡ ÀÇÇÑ »ý¹°ÇÐÀû ³ëÃâÀ» ÃÖ¼ÒÈ­ÇÕ´Ï´Ù. Ŭ·¡½º I, Ŭ·¡½º II ¹× Ŭ·¡½º III·Î ºÐ·ùµË´Ï´Ù. Ŭ·¡½º I ijºñ´ÖÀº »ç¿ëÀÚ¿Í ÁÖº¯ ȯ°æÀ» º¸È£ÇÕ´Ï´Ù. Ŭ·¡½º II ijºñ´ÖÀº »ç¿ëÀÚ, ȯ°æ ¹× »ùÇÃÀ» º¸È£ÇÏ°í Àú-Áߵ À§Çè »ý¹°ÇÐÀû Á¦Á¦¿¡ »ç¿ëµÇ¸ç, Ŭ·¡½º III ijºñ´ÖÀº °¡½º ¹ÐÆó¸¦ ÅëÇØ ÃÖ´ëÇÑÀÇ º¸È£ ±â´ÉÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ Ä³ºñ´ÖÀº Á¦Ç° Ç°ÁúÀ» ÃÖÀûÀ¸·Î Á¦¾îÇÏ°í ÀáÀçÀûÀÎ ¿À¿° À§ÇèÀ» ÃÖ¼ÒÈ­Çϱâ À§ÇØ ´Ù¾çÇÑ º¸È£ ¼öÁØÀ» Á¦°øÇϵµ·Ï »ç¿ëÀÚ Á¤ÀÇ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÇöÀç ÁøÇà ÁßÀÎ ¹ÙÀÌ·¯½º ÆÒµ¥¹Í°ú ´õºÒ¾î Àü¿°º´ À§ÇèÀÇ Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ´Â Áß¿äÇÑ ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. Äڷγª ¹ÙÀÌ·¯½º °¨¿°Áõ(COVID-19)ÀÌ Àü ¼¼°èÀûÀ¸·Î È®»êµÇ¸é¼­ ÀÇ·á ¼¾ÅÍÀÇ BSC¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡ÇÏ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, »ý¹°ÇÐÀû À§Çè¿¡ ´ëÇÑ ³ëÃâ ¹× ±³Â÷ ¿À¿°À¸·ÎºÎÅÍ Á¦Ç°, Àη ¹× ȯ°æÀ» º¸È£ÇØ¾ß ÇÒ Çʿ伺ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀå ¼ºÀå¿¡ ź·ÂÀ» ¹Þ°í ÀÖÀ¸¸ç, BSC´Â Áø´Ü ½ÇÇè½Ç ¹× Á¦¾à Á¦Á¶¾÷ü°¡ ¾à¹°ÀÇ ¹Ì»ý¹°ÇÐÀû Ç°ÁúÀ» À¯ÁöÇϱâ À§ÇØ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ±¸Á¶, ±â·ù ÆÐÅÏ, À¯¼Ó ¹× ¹è±â ½Ã½ºÅÛÀ» °³¼±ÇÑ Ä³ºñ´ÖÀÇ °³¹ß µî ´Ù¾çÇÑ Á¦Ç° Çõ½ÅÀÌ ¼ºÀåÀ» ÃËÁøÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇÏ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ijºñ´ÖÀ» ½±°Ô Á¦¾îÇÒ ¼ö ÀÖ´Â µðÁöÅÐ ÀÎÅÍÆäÀ̽º¿Í ȯ°æÀÇ ¹«±Õ »óŸ¦ À¯ÁöÇϱâ À§ÇÑ °íÈ¿À² ¹Ì¸³ÀÚ °ø±â(HEPA) ÇÊÅÍ°¡ ÀåÂøµÇ¾î ÀÖ½À´Ï´Ù. ÀÇ·á ÀÎÇÁ¶óÀÇ °³¼±°ú ÇÔ²² °Ë»ç ÀåºñÀÇ ±Þ¼ÓÇÑ Çö´ëÈ­ µî ´Ù¸¥ ¿äÀε鵵 ½ÃÀåÀ» ´õ¿í °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·ç´Â ÁÖ¿ä Áú¹®

  • ¼¼°è »ý¹° ¾ÈÀü ijºñ´Ö ½ÃÀåÀº Áö±Ý±îÁö ¾î¶»°Ô ¼ºÀåÇØ ¿ÔÀ¸¸ç, ¾ÕÀ¸·Î ¾î¶»°Ô ¹ßÀüÇÒ °ÍÀΰ¡?
  • COVID-19´Â ¼¼°è »ý¹° ¾ÈÀü ijºñ´Ö ½ÃÀå¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÄ¡°í Àִ°¡?
  • ÁÖ¿ä Áö¿ª ½ÃÀåÀ̶õ?
  • À¯Çüº° ½ÃÀå ºÐ¼®Àº?
  • ÃÖÁ¾»ç¿ëÀÚº° ½ÃÀå ºÐ¼®Àº?
  • »ê¾÷ °¡Ä¡»ç½½ÀÇ ´Ù¾çÇÑ ´Ü°è´Â ¹«¾ùÀΰ¡?
  • ¾÷°èÀÇ ÁÖ¿ä ÃËÁø¿äÀΰú °úÁ¦´Â ¹«¾ùÀΰ¡?
  • ¼¼°è »ý¹° ¾ÈÀü ijºñ´Ö ½ÃÀå ±¸Á¶¿Í ÁÖ¿ä ¾÷ü´Â?
  • ¾÷°èÀÇ °æÀïÀº ¾î´À Á¤µµÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

  • Á¶»ç ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • »óÇâ½Ä Á¢±Ù
    • ÇÏÇâ½Ä Á¢±Ù
  • Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼Ò°³

  • °³¿ä
  • ÁÖ¿ä ¾÷°è µ¿Çâ

Á¦5Àå ¼¼°èÀÇ »ý¹° ¾ÈÀü ijºñ´Ö ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ³»¿ª : À¯Çüº°

  • Ŭ·¡½º I
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • Ŭ·¡½º II
    • ½ÃÀå µ¿Çâ
    • ÁÖ¿ä Á¾·ù
      • Ŭ·¡½º II À¯Çü A
      • Ŭ·¡½º II À¯Çü B
    • ½ÃÀå ¿¹Ãø
  • Ŭ·¡½º III
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦7Àå ½ÃÀå ³»¿ª : ÃÖÁ¾»ç¿ëÀÚº°

  • Á¦¾à¡¤¹ÙÀÌ¿ÀÀǾàÇ° ±â¾÷
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • Áø´Ü ¹× °Ë»ç ¿¬±¸¼Ò
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • Çмú¿¬±¸±â°ü
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦8Àå ½ÃÀå ³»¿ª : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • Àεµ³×½Ã¾Æ
    • ±âŸ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ³»¿ª : ±¹°¡º°
    • ½ÃÀå ¿¹Ãø

Á¦9Àå SWOT ºÐ¼®

  • °³¿ä
  • °­Á¡
  • ¾àÁ¡
  • ±âȸ
  • À§Çù

Á¦10Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦11Àå Porter's Five Forces ºÐ¼®

  • °³¿ä
  • ±¸¸ÅÀÚÀÇ ±³¼··Â
  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • °æÀï Á¤µµ
  • ½Å±Ô Âü¿©¾÷üÀÇ À§Çù
  • ´ëüǰÀÇ À§Çù

Á¦12Àå °¡°Ý ºÐ¼®

Á¦13Àå °æÀï »óȲ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ °³¿ä
    • Air Science
    • Berner International
    • BIOBASE
    • Esco Micro Pte Ltd.
    • EUROCLONE SPA(AddLife Development AB)
    • Germfree Laboratories
    • Kewaunee Scientific Corporation
    • Labconco
    • NuAire(Polypipe)
    • The Baker Company, Inc.
    • Thermo Fisher Scientific Inc.
ksm 24.09.23

The global biological safety cabinet market size reached US$ 239.3 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 430.8 Million by 2032, exhibiting a growth rate (CAGR) of 6.5% during 2024-2032.

A biological safety cabinet (BSC) refers to a ventilated laboratory workspace designed for protecting workers and equipment from contamination through various pathogens. The cabinets minimize the biological exposure from harmful viruses, bacteria and other microorganisms. They are classified into three classes I, II and III. Class I cabinets protect the user and the surrounding environment. Class II cabinets protect the user, environment and the samples and are used for low to moderate risk biological agents and class III cabinets offer maximum protection through gas-tight enclosures. They can be customized to provide different protection levels to obtain optimum control over product quality and minimize the potential risks of contamination.

The increasing risks of communicable diseases, along with the on-going viral pandemic, is among the key factors driving the growth of the market. As the coronavirus disease (COVID-19) continues to spread across the globe, there has been a significant increase in the demand for BSCs in healthcare centers. Furthermore, the rising requirement to safeguard the product, personnel and environment from biohazard exposure and cross-contamination is providing a thrust to the market growth. BSCs are widely used by diagnostic labs and pharmaceutical manufacturers to maintain the microbiological quality of drugs. Additionally, various product innovations, such as the development of cabinet variants with improved construction, airflow pattern, velocities and exhaust systems, are acting as other growth-inducing factors. They are also equipped with digital interfaces for easy control of the cabinet and high-efficiency particulate air (HEPA) filters to maintain the sterility of the environment. Other factors, including the rapid modernization of laboratory equipment, along with improvements in the healthcare infrastructure, are anticipated to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global biological safety cabinet market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on type and end user.

Breakup by Type:

Class I

Class II

Class II Type A

Class II Type B

Class III

Breakup by End User:

Pharmaceutical and Biopharmaceutical Companies

Diagnostic and Testing Laboratories

Academic and Research Institutions

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Air Science, Berner International, BIOBASE, Esco Micro Pte Ltd., EUROCLONE SPA (AddLife Development AB), Germfree Laboratories, Kewaunee Scientific Corporation, Labconco, NuAire (Polypipe), The Baker Company, Inc. and Thermo Fisher Scientific Inc.

Key Questions Answered in This Report:

  • How has the global biological safety cabinet market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global biological safety cabinet market?
  • What are the key regional markets?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global biological safety cabinet market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Biological Safety Cabinet Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Class I
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Class II
    • 6.2.1 Market Trends
    • 6.2.2 Major Types
      • 6.2.2.1 Class II Type A
      • 6.2.2.2 Class II Type B
    • 6.2.3 Market Forecast
  • 6.3 Class III
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by End User

  • 7.1 Pharmaceutical and Biopharmaceutical Companies
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Diagnostic and Testing Laboratories
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Academic and Research Institutions
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Air Science
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
    • 13.3.2 Berner International
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
    • 13.3.3 BIOBASE
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
    • 13.3.4 Esco Micro Pte Ltd.
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
    • 13.3.5 EUROCLONE SPA (AddLife Development AB)
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
    • 13.3.6 Germfree Laboratories
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
    • 13.3.7 Kewaunee Scientific Corporation
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
    • 13.3.8 Labconco
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
    • 13.3.9 NuAire (Polypipe)
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
    • 13.3.10 The Baker Company, Inc.
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
    • 13.3.11 Thermo Fisher Scientific Inc.
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio
      • 13.3.11.3 Financials
      • 13.3.11.4 SWOT Analysis
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦